company mission and therapeutic approach to cancer treatment
MAIA's stated mission did not meaningfully change between September 26, 2020 and January 18, 2021. In both snapshots, the company says it is developing first in class targeted therapy and immuno oncology drugs with novel mechanisms of action to improve and extend the lives of people with cancer. The therapeutic pitch is stable: cancer treatment through new drug mechanisms, framed as both targeted therapy and immuno oncology. The operating model is just as stable. In both versions, MAIA says each drug candidate should sit inside a dedicated R&D focused subsidiary, while central infrastructure and management stay shared. That is a specific corporate belief, not just a mission statement, and it appears intact across both dates. What changed is basically wording polish. The January 2021 version tightens a few phrases, but the substance stays the same. With only two Wayback snapshots, both close together, the evidence is thin. We can say the company's public self description was highly consistent across this period, but we cannot say from these entries alone whether that consistency held before September 2020 or evolved later.